Replies to post #14874 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I generally look at the classic view as well. They are 18 month late for an extension, and no new trial was submitted which would have had to be registered and posted by October 27, 2022. Therefore, I don't believe a extension for good cause qualifies. Really looking like a certification request.

If AbbVie is involved, I believe they are waiting for July 1, 2023 when the Michael A. Roberts officially assumes the helm, as CEO. A good way to start under a new CEO.

Now, they don't have to worry about the Pre-notice for non compliance in submitting results coming out now until the first week of July.

JMHO